|
Kidney diseases associated with haematological cancers - Nature.com |
Nature.com
Advances in chemotherapy for haematological malignancies, resulting from a greater understanding of the complex pathophysiology of these diseases, have improved the survival of patients with these disorders. Clinicians must now, therefore, be more
|
|
Parathyroidectomy Rarely Used in Renal-Transplant Patients - Medscape |
|
 Parathyroidectomy Rarely Used in Renal-Transplant Patients
Medscape
Nashville, Tennessee — Very few renal-transplant patients with tertiary hyperparathyroidism are undergoing parathyroidectomy, even though the surgery represents the only cure for the condition and does not appear to harm the kidney graft, a new ...
|
|
|
Urinary Cancers Not Linked to Lithium - Renal and Urology News |
June 02, 2015
Lithium, a medication used to treat bipolar disorders, does not appear to induce renal cancer.
A large, nationwide Danish study finds no association between long-term lithium use and the risks of upper urinary tract cancers.
Previously, a small-scale study had found a strong link between lithium, a medication commonly used to treat bipolar affective disorders, and genitourinary cancers. Preliminary animal and human studies had also raised the possibility that lithium's nephrotoxic effects extended to malignancy.
In Denmark, medical care is nationalized, allowing for comprehensive data capture on a population level. For the current study, investigators led by Anton Pottegard, PhD, a clinical pharmacist at the University of Southern Denmark, identified 6,477 histologically-verified upper urinary tract cancers cases from the Danish Cancer Registry between 2000 and 2012. The cancers included a first-time diagnosis of invasive cancer of the kidney, renal pelvis, or ureter. Cases were then matched by age and sex to 259,080 controls. Based on the Danish Prescription Registry, less than a quarter percent of cases and controls were taking lithium for at least 5 years.
According to findings published online ahead of print in the Journal of the American Society of Nephrology,long-term use of lithium was linked to a non-significant 30% increased odds of the cancers. Even in the worst case scenario, researchers estimated that it would take 3,091 person-years of lithium exposure to see 1 additional cancer case. Analyses by cancer stage and subtype also revealed only slight, non-significant increased odds. Results were adjusted for other drugs, diseases, and socioeconomic factors believed to affect the kidney.
“In conclusion, we can exclude any major effect of long-term lithium use on the risk of renal cancer or cancers of the renal pelvis or ureter,” the investigators wrote. “Although long-term lithium use may be associated with other renal adverse effects, it is reassuring that lithium use does not appear to induce renal cancer, and that lithium can be kept on the armamentarium for conditions as debilitating as bipolar disorder and severe unipolar depression.”
The researchers noted that their findings might be affected by surveillance bias, “as lithium users frequently undergo renal function tests and generally have more frequent contact with the health care system compared with individuals without bipolar disorder or severe depression, and no lithium use.”
Source
- Pottegard, A, et al. Journal of the American Society of Nephrology; doi: 10.1681/ASN.2015010061.
|
|
Volume Movers: Rockwell Medical (NASDAQ:RMTI), Key Energy Services ... - wsnewspublishers |
|
On Monday, Rockwell Medical Inc (NASDAQ:RMTI)’s shares inclined 3.61% to $11.47.
Rockwell Medical Inc (RMTI) a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, declared recently that the Centers for Medicare and Medicaid Services (CMS) has granted a unique product reimbursement code for Triferic. The Level II Healthcare Common Procedure Coding System (HCPCS) product reimbursement Q-code (Q9976) will assist facilitate the billing process for dialysis organizations using Triferic. This new Q-code will become effective on July 1, 2015. Triferic is the only iron product that is FDA approved for delivery via dialysate to replace iron and maintain hemoglobin to treat anemia in the hemodialysis patient population in the United States. Rockwell Medical, Inc. operates as an integrated biopharmaceutical company in the United States and internationally. It offers products and services for the treatment of end-stage renal disease, chronic kidney disease, iron deficiency, secondary hyperparathyroidism, and hemodialysis. Key Energy Services, Inc. (NYSE:KEG)’s shares dropped -2.22% to $2.20. Key Energy Services, Inc. (KEG) declared that it has closed a $100 million asset-based revolving credit facility (“ABL”) due February 2020 and closed and funded a $315 million term loan facility due June 2020 (together, the “Facilities”). The Facilities replace Key’s existing $400 million senior revolving credit facility. The Facilities do not have cash flow based financial maintenance covenants; however, the Facilities require Key to maintain $100 million in liquidity, counting cash and availability under the ABL. Upon closing, Key had $270.6 million of liquidity, assuming the completion of certain post-closing collateral perfection requirements. The Facilities also require Key to maintain the ratio of the net orderly liquidation value of its assets and certain term loan proceeds to term loan borrowings of 1.5x. As of the date of closing, this ratio was 2.15x. The ABL also comprises a fixed charge coverage ratio of 1.0x, which is tested only if excess availability under the ABL falls below a specified threshold or upon the occurrence of certain other events. The term loan was issued at an OID of 3.0% with an annual rate of LIBOR plus 9.25% with a 1.00% LIBOR floor. The ABL bears interest at an annual rate on outstanding borrowings of LIBOR plus 4.5%, with a fee on unused commitments ranging from 1.00% – 1.25% based on utilization. Key plans to file copies of the Facilities with the U.S. Securities and Exchange Commission as exhibits to a Current Report on Form 8-K, and reference should be made to the Facilities for a complete description of their terms. Key Energy Services, Inc. operates as an onshore rig-based well servicing contractor in the United States and internationally. It offers rig-based services, counting the maintenance, workover, and recompletion of existing oil wells; completion of newly-drilled wells; and plugging and abandonment of wells at the end of their lives, in addition to specialty drilling services to oil and natural gas producers. At the end of Monday’s trade, ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS)‘s shares dipped -0.56% to $66.94. ISIS Pharmaceuticals, Inc. (ISIS) declares the Akcea Therapeutics Webcast on Thursday, June 4 at 1:00 p.m. ET / 10:00 a.m. PT. Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. The company’s flagship product comprises the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia; and for the reduction of low-density lipoprotein cholesterol. It also has a pipeline of 38 drugs in development for the treatment of various diseases, counting cardiovascular and metabolic diseases; severe and rare diseases, which comprise neurological disorders; and cancer. Five Below Inc (NASDAQ:FIVE), ended its Monday’s trading session with 1.86% gain, and closed at $33.87. Five Below Inc (FIVE) declared the Company will grand open a new distribution center in Oldmans Township, New Jersey. The 1,045,000 square-foot facility, located at 5 Gateway Boulevard, Pedricktown, NJ, will replace the Company’s existing 421,000 square foot facility located 12 miles away in New Castle, Delaware. Five Below will occupy about 700,000 square feet of the facility to start, with plans to grow to a million square feet over time. The new distribution center will support the Company’s continued growth and expansion in the Eastern U.S. Five Below will start shipping out of the new distribution center in July. The property is owned by NFI, a supply chain solutions provider headquartered in Cherry Hill, NJ. All of the current jobs at the New Castle facility will be transferred to the new Pedricktown facility. Additionally, over 100 new jobs are predictable to be created over the next few years. The Company will host a grand opening ceremony at the new facility at 9:00am EST on Wednesday, June 3rd, with local community and government officials. Five Below, Inc. operates as a specialty value retailer in the United States. It offers accessories, counting novelty socks, sunglasses, jewelry, scarves, gloves, hair accessories, athletic tops and bottoms, and t-shirts, in addition to beauty products comprising nail polish, lip gloss, fragrance, and branded cosmetics; and items used to complete and personalize living space, counting glitter lamps, posters, frames, fleece blankets, pillows, candles, incense and related items, and storage options for the customer’s room and locker. DISCLAIMER: This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article. All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision. Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
|
|
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
